In the long struggle against one of humanity's most lethal cancers, a new kind of medicine has quietly redrawn the boundary of what survival can mean. A large clinical trial conducted in China found that ivonescimab, a bispecific antibody targeting two tumor-sustaining pathways at once, extended the lives of advanced lung cancer patients by more than eight months compared to the current immunotherapy standard, pembrolizumab. The finding, emerging from nearly 400 patients followed over several years, represents not merely a statistical milestone but a reminder that the architecture of disease c
Ivonescimab Extends Survival in Advanced Lung Cancer vs. Pembrolizumab
The trial enrolled 398 patients with advanced lung cancer; ivonescimab demonstrated improved survival outcomes reducing mortality risk by 27% compared to standard treatment.